Protective effect of VK2 on glucocorticoid-treated MC3T3-E1 cells

Zhang,Yue-Lei; Yin,Jun-Hui; Ding,Hao; Zhang,Wei; Zhang,Chang-Qing; Gao,You-Shui

doi:10.3892/ijmm.2016.2817

Protective effect of VK2 on glucocorticoid-treated MC3T3-E1 cells

Authors:
- Yue-Lei Zhang
- Jun-Hui Yin
- Hao Ding
- Wei Zhang
- Chang-Qing Zhang
- You-Shui Gao
View Affiliations

Affiliations: Department of Orthopedic Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai 200233, P.R. China
Published online on: December 1, 2016 https://doi.org/10.3892/ijmm.2016.2817
Pages: 160-166
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Glucocorticoids (GCs) contribute to the increased incidence of secondary osteoporosis and osteonecrosis, and medications for the prevention and treatment of these complications have been investigated for many years. Vitamin K2 (VK2) has been proven to promote bone formation both in vitro and in vivo. In this study, we examined the effects of VK2 on dexamethasone (DEX)-treated MC3T3-E1 osteoblastic cells. We observed that VK2 promoted the proliferation and enhanced the survival of dexamethasone-treated MC3T3-E1 cells. In addition, VK2 upregulated the expression levels of osteogenic marker proteins, such as Runt-related transcription factor 2 (Runx2), alkaline phosphatase (ALP) and osteocalcin, which were significantly inhibited by dexamethasone. On the whole, our findings indicate that VK2 has the potential to antagonize the effects of GCs on MC3T3-E1 cells, and may thus prove to be a promising agent for the prevention and treatment of GC-induced osteoporosis and osteonecrosis.

View Figures

View References

1	Kim BY, Yoon HY, Yun SI, Woo ER, Song NK, Kim HG, Jeong SY and Chung YS: In vitro and in vivo inhibition of glucocorticoid-induced osteoporosis by the hexane extract of Poncirus trifoliata. Phytother Res. 25:1000–1010. 2011. View Article : Google Scholar : PubMed/NCBI
2	Weinstein RS: Glucocorticoid-induced osteonecrosis. Endocrine. 41:183–190. 2012. View Article : Google Scholar
3	Koromila T, Baniwal SK, Song YS, Martin A, Xiong J and Frenkel B: Glucocorticoids antagonize RUNX2 during osteoblast differentiation in cultures of ST2 pluripotent mesenchymal cells. J Cell Biochem. 115:27–33. 2014. View Article : Google Scholar
4	Kerachian MA, Séguin C and Harvey EJ: Glucocorticoids in osteonecrosis of the femoral head: a new understanding of the mechanisms of action. J Steroid Biochem Mol Biol. 114:121–128. 2009. View Article : Google Scholar : PubMed/NCBI
5	Tan G, Kang PD and Pei FX: Glucocorticoids affect the metabolism of bone marrow stromal cells and lead to osteonecrosis of the femoral head: a review. Chin Med J (Engl). 125:134–139. 2012. View Article : Google Scholar
6	Kim J, Lee H, Kang KS, Chun KH and Hwang GS: Protective effect of Korean Red Ginseng against glucocorticoid-induced osteoporosis in vitro and in vivo. J Ginseng Res. 39:46–53. 2015. View Article : Google Scholar
7	O'Brien CA, Jia D, Plotkin LI, Bellido T, Powers CC, Stewart SA, Manolagas SC and Weinstein RS: Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology. 145:1835–1841. 2004. View Article : Google Scholar
8	Weinstein RS, Jilka RL, Parfitt AM and Manolagas SC: Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest. 102:274–282. 1998. View Article : Google Scholar : PubMed/NCBI
9	Yun SI, Yoon HY, Jeong SY and Chung YS: Glucocorticoid induces apoptosis of osteoblast cells through the activation of glycogen synthase kinase 3beta. J Bone Miner Metab. 27:140–148. 2009. View Article : Google Scholar
10	Weinstein RS, Chen JR, Powers CC, Stewart SA, Landes RD, Bellido T, Jilka RL, Parfitt AM and Manolagas SC: Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J Clin Invest. 109:1041–1048. 2002. View Article : Google Scholar : PubMed/NCBI
11	Hamidi MS, Gajic-Veljanoski O and Cheung AM: Vitamin K and bone health. J Clin Densitom. 16:409–413. 2013. View Article : Google Scholar : PubMed/NCBI
12	Azuma K, Ouchi Y and Inoue S: Vitamin K: novel molecular mechanisms of action and its roles in osteoporosis. Geriatr Gerontol Int. 14:1–7. 2014. View Article : Google Scholar
13	Yamaguchi M, Sugimoto E and Hachiya S: Stimulatory effect of menaquinone-7 (vitamin K₂) on osteoblastic bone formation in vitro. Mol Cell Biochem. 223:131–137. 2001. View Article : Google Scholar : PubMed/NCBI
14	Shearer MJ and Newman P: Recent trends in the metabolism and cell biology of vitamin K with special reference to vitamin K cycling and MK-4 biosynthesis. J Lipid Res. 55:345–362. 2014. View Article : Google Scholar : PubMed/NCBI
15	Igarashi M, Yogiashi Y, Mihara M, Takada I, Kitagawa H and Kato S: Vitamin K induces osteoblast differentiation through pregnane X receptor-mediated transcriptional control of the Msx2 gene. Mol Cell Biol. 27:7947–7954. 2007. View Article : Google Scholar : PubMed/NCBI
16	Kim M, Na W and Sohn C: Vitamin K₁ (phylloquinone) and K₂ (menaquinone-4) supplementation improves bone formation in a high-fat diet-induced obese mice. J Clin Biochem Nutr. 53:108–113. 2013. View Article : Google Scholar : PubMed/NCBI
17	Koshihara Y, Hoshi K, Okawara R, Ishibashi H and Yamamoto S: Vitamin K stimulates osteoblastogenesis and inhibits osteoclastogenesis in human bone marrow cell culture. J Endocrinol. 176:339–348. 2003. View Article : Google Scholar : PubMed/NCBI
18	Atkins GJ, Welldon KJ, Wijenayaka AR, Bonewald LF and Findlay DM: Vitamin K promotes mineralization, osteoblast-to-osteocyte transition, and an anticatabolic phenotype by {gamma}-carboxylation-dependent and -independent mechanisms. Am J Physiol Cell Physiol. 297:C1358–C1367. 2009. View Article : Google Scholar : PubMed/NCBI
19	Koshihara Y and Hoshi K: Vitamin K₂ enhances osteocalcin accumulation in the extracellular matrix of human osteoblasts in vitro. J Bone Miner Res. 12:431–438. 1997. View Article : Google Scholar : PubMed/NCBI
20	Akiyama Y, Hara K, Ohkawa I and Tajima T: Effects of menatetrenone on bone loss induced by ovariectomy in rats. Jpn J Pharmacol. 62:145–153. 1993. View Article : Google Scholar : PubMed/NCBI
21	Iwamoto J, Matsumoto H, Takeda T, Sato Y and Yeh JK: Effects of vitamin K₂ on cortical and cancellous bone mass, cortical osteocyte and lacunar system, and porosity in sciatic neurectomized rats. Calcif Tissue Int. 87:254–262. 2010. View Article : Google Scholar : PubMed/NCBI
22	Iwamoto J, Seki A, Sato Y, Matsumoto H, Tadeda T and Yeh JK: Vitamin K₂ promotes bone healing in a rat femoral osteotomy model with or without glucocorticoid treatment. Calcif Tissue Int. 86:234–241. 2010. View Article : Google Scholar : PubMed/NCBI
23	Koitaya N, Sekiguchi M, Tousen Y, Nishide Y, Morita A, Yamauchi J, Gando Y, Miyachi M, Aoki M, Komatsu M, et al: Low-dose vitamin K₂ (MK-4) supplementation for 12 months improves bone metabolism and prevents forearm bone loss in postmenopausal Japanese women. J Bone Miner Metab. 32:142–150. 2014. View Article : Google Scholar
24	Koitaya N, Ezaki J, Nishimuta M, Yamauchi J, Hashizume E, Morishita K, Miyachi M, Sasaki S and Ishimi Y: Effect of low dose vitamin K₂ (MK-4) supplementation on bio-indices in postmenopausal Japanese women. J Nutr Sci Vitaminol (Tokyo). 55:15–21. 2009. View Article : Google Scholar
25	Hara K, Akiyama Y, Ohkawa I and Tajima T: Effects of menatetrenone on prednisolone-induced bone loss in rats. Bone. 14:813–818. 1993. View Article : Google Scholar : PubMed/NCBI
26	Sasaki N, Kusano E, Takahashi H, Ando Y, Yano K, Tsuda E and Asano Y: Vitamin K₂ inhibits glucocorticoid-induced bone loss partly by preventing the reduction of osteoprotegerin (OPG). J Bone Miner Metab. 23:41–47. 2005. View Article : Google Scholar
27	van Staa TP, Leufkens HG and Cooper C: The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 13:777–787. 2002. View Article : Google Scholar : PubMed/NCBI
28	Tanana I and Oshima H: Vitamin K₂ as a potential therapeutic agent for glucocorticoid-induced osteoporosis. Clin Calcium. 16:1851–1857. 2006.In Japanese. PubMed/NCBI
29	Iwamoto J, Matsumoto H, Takeda T, Sato Y, Liu X and Yeh JK: Effects of vitamin K(2) and risedronate on bone formation and resorption, osteocyte lacunar system, and porosity in the cortical bone of glucocorticoid-treated rats. Calcif Tissue Int. 83:121–128. 2008. View Article : Google Scholar : PubMed/NCBI
30	Inoue T, Sugiyama T, Matsubara T, Kawai S and Furukawa S: Inverse correlation between the changes of lumbar bone mineral density and serum undercarboxylated osteocalcin after vitamin K₂ (menatetrenone) treatment in children treated with glucocorticoid and alfacalcidol. Endocr J. 48:11–18. 2001. View Article : Google Scholar : PubMed/NCBI
31	Sanderson M, Sadie-Van Gijsen H, Hough S and Ferris WF: The role of MKP-1 in the anti-proliferative effects of glucocorticoids in primary rat pre-osteoblasts. PLoS One. 10:e01353582015. View Article : Google Scholar : PubMed/NCBI
32	Shi C, Huang P, Kang H, Hu B, Qi J, Jiang M, Zhou H, Guo L and Deng L: Glucocorticoid inhibits cell proliferation in differentiating osteoblasts by microRNA-199a targeting of WNT signaling. J Mol Endocrinol. 54:325–337. 2015. View Article : Google Scholar : PubMed/NCBI
33	Stenhoff J, Dahlbäck B and Hafizi S: Vitamin K-dependent Gas6 activates ERK kinase and stimulates growth of cardiac fibroblasts. Biochem Biophys Res Commun. 319:871–878. 2004. View Article : Google Scholar : PubMed/NCBI
34	Kirane A, Ludwig KF, Sorrelle N, Haaland G, Sandal T, Ranaweera R, Toombs JE, Wang M, Dineen SP, Micklem D, et al: Warfarin blocks Gas6-mediated Axl activation required for pancreatic cancer epithelial plasticity and metastasis. Cancer Res. 75:3699–3705. 2015. View Article : Google Scholar : PubMed/NCBI
35	Calder JD, Buttery L, Revell PA, Pearse M and Polak JM: Apoptosis - a significant cause of bone cell death in osteonecrosis of the femoral head. J Bone Joint Surg Br. 86:1209–1213. 2004. View Article : Google Scholar : PubMed/NCBI
36	Sada E, Abe Y, Ohba R, Tachikawa Y, Nagasawa E, Shiratsuchi M and Takayanagi R: Vitamin K₂ modulates differentiation and apoptosis of both myeloid and erythroid lineages. Eur J Haematol. 85:538–548. 2010. View Article : Google Scholar : PubMed/NCBI
37	Hegarty JM, Yang H and Chi NC: UBIAD1-mediated vitamin K₂ synthesis is required for vascular endothelial cell survival and development. Development. 140:1713–1719. 2013. View Article : Google Scholar : PubMed/NCBI
38	Sakaue M, Mori N, Okazaki M, Kadowaki E, Kaneko T, Hemmi N, Sekiguchi H, Maki T, Ozawa A, Hara S, et al: Vitamin K has the potential to protect neurons from methylmercury-induced cell death in vitro. J Neurosci Res. 89:1052–1058. 2011. View Article : Google Scholar : PubMed/NCBI
39	Vos M, Esposito G, Edirisinghe JN, Vilain S, Haddad DM, Slabbaert JR, Van Meensel S, Schaap O, De Strooper B, Meganathan R, et al: Vitamin K₂ is a mitochondrial electron carrier that rescues pink1 deficiency. Science. 336:1306–1310. 2012. View Article : Google Scholar : PubMed/NCBI
40	Banerjee C, McCabe LR, Choi JY, Hiebert SW, Stein JL, Stein GS and Lian JB: Runt homology domain proteins in osteoblast differentiation: AML3/CBFA1 is a major component of a bone-specific complex. J Cell Biochem. 66:1–8. 1997. View Article : Google Scholar : PubMed/NCBI
41	Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, Shimizu Y, Bronson RT, Gao YH, Inada M, et al: Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell. 89:755–764. 1997. View Article : Google Scholar : PubMed/NCBI
42	Shimizu T, Takahata M, Kameda Y, Hamano H, Ito T, Kimura-Suda H, Todoh M, Tadano S and Iwasaki N: Vitamin K-dependent carboxylation of osteocalcin affects the efficacy of teriparatide (PTH(1–34)) for skeletal repair. Bone. 64:95–101. 2014. View Article : Google Scholar : PubMed/NCBI
43	Neve A, Corrado A and Cantatore FP: Osteocalcin: skeletal and extra-skeletal effects. J Cell Physiol. 228:1149–1153. 2013. View Article : Google Scholar
44	Horie-Inoue K and Inoue S: Steroid and xenobiotic receptor mediates a novel vitamin K₂ signaling pathway in osteoblastic cells. J Bone Miner Metab. 26:9–12. 2008. View Article : Google Scholar
45	Ichikawa T, Horie-Inoue K, Ikeda K, Blumberg B and Inoue S: Steroid and xenobiotic receptor SXR mediates vitamin K₂-activated transcription of extracellular matrix-related genes and collagen accumulation in osteoblastic cells. J Biol Chem. 281:16927–16934. 2006. View Article : Google Scholar : PubMed/NCBI
46	Manolagas SC: Steroids and osteoporosis: the quest for mechanisms. J Clin Invest. 123:1919–1921. 2013. View Article : Google Scholar : PubMed/NCBI
47	Yoshiji H, Kuriyama S, Noguchi R, Yoshii J, Ikenaka Y, Yanase K, Namisaki T, Kitade M, Yamazaki M, Masaki T and Fukui H: Combination of vitamin K₂ and the angiotensin-converting enzyme inhibitor, perindopril, attenuates the liver enzyme-altered preneoplastic lesions in rats via angiogenesis suppression. J Hepatol. 42:687–693. 2005. View Article : Google Scholar : PubMed/NCBI